Tag Archives: Postpartum

Brexanolone (Zulresso) for Postpartum Depression Cleared by the DEA, Now Available

Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression.  At that time, we were told that Zulresso would be available in June 2019. Here are a few updates. The Drug Enforcement Administration (DEA) has recommended that brexanolone be placed in schedule IV of… Read More »

FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression

FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression Print this page March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression… Read More »